A venture capital firm made about $470 million on a buzzy biotech’s $8 billion acquisition, and has its eye on these promising areas next
|01/08/2019||Posted by BusinessMediaguide.Com under General World News||
- Eli Lilly & Co.’s about $8 billion acquisition of biotech Loxo Oncology could mean a $470 million payday for venture-capital firm Aisling Capital.
- Aisling Capital was a founding investor in Loxo and most recently held a 6.6% stake.
- Aisling Capital managing partner Steve Elms told Business Insider about the other biotechs and scientific areas the firm is intrigued by.
Pharma giant Eli Lilly & Co.’s Monday acquisition of biotech Loxo Oncology for $8 billion was a big deal, both for Eli Lilly and the wider biopharmaceutical industry.
It also represents a major payday for venture-capital firm Aisling Capital, with expected returns read more >>>